Instead, the fact that PD-L1-induced activation of STAT3 and STAT1 requires, as a prerequisite, that PD-L1 will be N-linked glycosylated, provides novel perspectives to PD-L1-directed therapy in breast cancer patients. The gene discussed is CD274; the disease is breast carcinoma.